New antibody may offer safer shield against transplant complications

NCT ID NCT07689630

Recruiting now Disease control Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Source: ClinicalTrials.gov ↗

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This phase 3 trial compares an anti-CD25 monoclonal antibody (daclizumab) with methotrexate for preventing acute graft-versus-host disease (GVHD) in people with blood cancers receiving a half-matched stem cell transplant. GVHD is a serious complication where donor immune cells attack the patient's body. The study aims to see if the antibody can reduce GVHD and side effects like mouth sores and slow blood recovery. Participants are randomly assigned to receive either the antibody or methotrexate, along with standard GVHD prevention drugs.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Anti-CD25 monoclonal antibody (daclizumab)
What this could lead to: If successful, this could offer a safer way to prevent graft-versus-host disease after stem cell transplants, reducing side effects like mouth sores and slow blood recovery.
What could go wrong: This is an early-phase trial with 186 participants, so results may not apply to all patients. The anti-CD25 antibody could still cause infections or other complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GRAFT VERSUS HOST DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

graft versus host disease hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm acute graft versus host disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GRAFT VERSUS HOST DISEASE HEMATOLOGIC NEOPLASMS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITING

Wuhan, Hubei, 430022, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.